Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Norris S, Ramael S, Ikushima I, Haazen W, Harada A, Moschetti V, Imazu S, Reilly PA, Lang B, Stangier J, Glund S.
Norris S, et al. Among authors: ikushima i.
Br J Clin Pharmacol. 2017 Aug;83(8):1815-1825. doi: 10.1111/bcp.13269. Epub 2017 Apr 6.
Br J Clin Pharmacol. 2017.
PMID: 28230262
Free PMC article.
Clinical Trial.